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Abstract
Background: UK public health organisations perform routine antimicrobial susceptibility tests (ASTs) to characterise the
potential for antimicrobial resistance in Salmonella enterica serovars. Genetic determinants of these resistance mechanisms
are detectable by whole genome sequencing (WGS), however the viability of WGS-based genotyping as an alternative
resistance screening tool remains uncertain. We compared WGS-based genotyping, disk diffusion and agar dilution to the
broth microdilution reference AST for 102 Salmonella enterica serovar Typhimurium (S. Typhimurium) isolates across 11
antimicrobial compounds.
Results: Genotyping concordance, interpreted using epidemiological cut-offs (ECOFFs), was 89.8% (1007/1122) with
0.83 sensitivity and 0.96 specificity. For seven antimicrobials interpreted using Salmonella clinical breakpoints,
genotyping produced 0.84 sensitivity and 0.88 specificity. Although less accurate than disk diffusion (0.94 sensitivity,
0.93 specificity) and agar dilution (0.83 sensitivity, 0.98 specificity), genotyping performance improved to 0.89 sensitivity
and 0.97 specificity when two antimicrobials with relatively high very major error rates were excluded (streptomycin
and sulfamethoxazole).
Conclusions: An 89.8% concordance from WGS-based AST predictions using ECOFF interpretations suggest that WGS
would serve as an effective screening tool for the tracking of antimicrobial resistance mechanisms in S. Typhimurium. For
use as a standalone clinical diagnostic screen, further work is required to reduce the error rates for specific antimicrobials.
Keywords: Antimicrobial susceptibility tests, Whole genome sequencing, Disk diffusion, Agar dilution, Broth microdilution,
Salmonella enterica serovar typhimurium
Background
Antimicrobial resistance (AMR) is a global health emer-
gency. In the EU alone, drug-resistant infections result
in healthcare costs of at least €1.5 billion per year [1, 2].
The ability to rapidly acquire genetic elements confer-
ring resistance to antimicrobial drugs from the environ-
ment contributes to the survivability of infectious
foodborne pathogens. Among these, Salmonella enterica
serovar Typhimurium (S. Typhimurium) is one of the
most common sub-species isolated from livestock in the
UK [3]. In humans, drug-resistant S. Typhimurium has
been associated with a higher risk of infection, frequency of
hospitalization, illness and risk of death than pan-
susceptible strains [1]. Accurate, rapid and cost-effective
classification of AMR in infectious agents such as S. Typhi-
murium is therefore critical to managing disease burden.
The broth microdilution antimicrobial susceptibility
test (AST) is defined in the International Standards
Organisation standard 20,776–1:2006 [4] as the
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reference method for testing the in vitro activity of
antimicrobial agents against infectious bacteria. This test
determines the minimum inhibitory concentration
(MIC) of an antimicrobial required to limit bacterial
growth. Although broth microdilution is the mandated
method for reporting AMR surveillance in the EU
harmonised surveillance programme, many research and
surveillance laboratories maintain the use of legacy refer-
ence AST methods. For example, resistance in bacterial
isolates submitted to UK veterinary laboratories is mea-
sured using the disk diffusion AST [5]. Phenotypic ASTs
determine the viability of bacteria in response to anti-
microbial exposure and are therefore unable to distin-
guish between the genetic mechanisms responsible. At
most, the cumulative effect of underlying AMR mecha-
nisms may be inferred from ASTs using interpretive
criteria. For this purpose, whole genome sequencing
(WGS) is a high-resolution assay capable of identifying
molecular AMR mechanisms in S. Typhimurium and
other bacteria [6–8]. Developments in next generation
sequencing technologies have led to a steady decrease in
the cost of WGS; WGS has been performed for as little
as £40 per bacterial genome and in the past decade, this
and the increasing availability of the technology has been
reflected in the greater than 100-fold increase in publicly
available genomes [9, 10]. In a single assay, WGS is able
to facilitate subspecies typing, AMR prediction and
phylogenetic source attribution, prompting international
efforts to validate WGS informatics pipelines for surveil-
lance applications [11].
Previous assessments of Salmonella AMR identified
through WGS have predominantly used a single pheno-
typic AST method in comparisons, such as disk diffusion
[12, 13], agar dilution [14] and broth microdilution [6].
To determine robustly the utility of WGS for AMR pre-
diction, comparisons against multiple phenotypic tests
representing clinical and veterinary screening environ-
ments are required. Whereas ASTs interpreted using
clinical breakpoints inform clinicians of the potential for
antimicrobial treatment failure, epidemiological cut-offs
(ECOFFs) dictate the upper-limit MIC for isolates de-
void of acquired resistance mechanisms as determined
by a species-specific MIC population distribution. To
facilitate meta-analysis, the European Committee on
Antimicrobial Susceptibility testing (EUCAST) subcom-
mittee recommends ECOFFs as the primary interpretive
criteria for WGS comparisons against phenotypic ASTs,
along with secondary analyses using clinical breakpoints
on the same data set [15]. This study contributes to the
growing evidence base assessing WGS for bacterial
AMR determinations by comparing S. Typhimurium
genotyping predictions as assessed by WGS to the broth
microdilution reference method using both interpretive
criteria. Additionally, agar dilution and disk diffusion
ASTs are compared to determine the utility of WGS
against these alternative screening methods.
Methods
Isolate selection
One hundred and two S. Typhimurium isolates, isolated
between 1992 and 2012, were cultured from the Animal
and Plant Health Agency (APHA, Addlestone, UK)
strain collection. Duplicate strains were not identified or
excluded, however the selection criteria involved rando-
mised selection of isolates; a minimum of two per year
across a 20 year timeframe. At the time of submission,
all isolates were serotyped in accordance with the
White-Kauffman-Le Minor scheme [16] and phenotypic
AMR profiles were determined by disk diffusion.
Selection criteria therefore included a minimum of two
isolates per year and a range of overlapping phenotypic
AMR profiles. Additional quality controls were provided
by repeated serotyping and disk diffusion testing to
confirm the phenotype of the selected strains.
Antimicrobial susceptibility testing
Reference broth microdilution MICs were obtained
using the Sensititre™ Complete Automated System with
EUVSEC and CMV3AGNF panels (Trek Diagnostic
Systems, West Sussex, UK). ECOFFs published by
EUCAST [17] were applied to these results. In the cases
of sulfamethoxazole and sulfisoxazole, ECOFFs could
not be established from EUCAST data therefore the
>256 μg/mL ECOFF used in the EFSA/ECDC and
NARMS monitoring programs was applied [18, 19].
Wild-type (WT) and non-wild-type (NWT) resistance
profiles were determined for 11 antimicrobials, repre-
senting a subset of those historically evaluated in
Salmonella AMR screening at the APHA: ampicillin
(Amp), chloramphenicol (Chl), ciprofloxacin (Cip),
gentamicin (Gen), nalidixic acid (Nal), streptomycin
(Str), sulfamethoxazole (Smx), trimethoprim/sulfameth-
oxazole (1:19) (Sxt), sulfisoxazole (Sul), tetracycline (Tet)
and trimethoprim (Tri).
Seven antimicrobials were selected from this initial list
for resistance profiling by disk diffusion and agar
dilution ASTs. This selection was made based on the
available clinical breakpoints for both phenotyping
methods. Antimicrobial disks (Thermo-Fisher Scientific
Ltd) and antimicrobial powders (Sigma-Aldrich)
containing ampicillin, chloramphenicol, gentamicin, nali-
dixic acid, streptomycin, sulfamethoxazole and trimetho-
prim/sulfamethoxazole (1:19) were used to determine
clinical resistance profiles. Specifically, disk diffusion
tests were conducted on Isosensitest Agar (Oxoid)
following the Kirby-Bauer method described by the Brit-
ish Society for Antimicrobial Chemotherapy (BSAC)
[20]. Although legacy zone diameter readings informed
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isolate selection, disk diffusion testing was repeated for
this study to account for temporal factors in compari-
sons with phenotypic and genotypic ASTs. Isolates were
tested by agar dilution using the method described by
Wiegand et al. [21]. Zone diameters and MICs deter-
mined by all phenotypic methods were interpreted using
EUCAST clinical breakpoints [22], with the following
exceptions: breakpoints for nalidixic acid and sulfon-
amides have not been determined by EUCAST, therefore
breakpoints published by the Clinical and Laboratory
Standards Institute were applied [23]; although no
longer used clinically, the legacy NARMS 64 μg/mL
streptomycin clinical breakpoint was used as in previous
studies [6]. Control strains E. coli ACTC25922 and E.
coli NCTC10418 were included for susceptibility test
validation. ECOFFs, clinical breakpoints, dilution ranges
and disk contents used are presented in Additional file
1: Table S1. All phenotyping results are presented in
Additional file 1: Table S2.
Whole genome sequencing and AMR genotyping
Bacterial DNA was extracted with the MagNA Pure LC
DNA Isolation Kit III (Roche) according to manufacturer’s
instructions and sequenced on the Illumina HiSeq platform
producing paired-end (2x125bp) reads. Acquired resistance
determinants were identified from WGS reads using
ARIBA [24] in combination with the Resfinder v3.0 data-
base [25]. Additionally, the presence of point mutations
associated with AMR was determined using Pointfinder
v3.0 [26]. Whole genome sequences of the 102 S. Typhi-
murium isolates were submitted to the European Nucleo-
tide Archive under the study accession PRJEB10999. WGS
AMR genotyping profiles and AMR gene accession num-
bers are presented in Additional file 1: Table S3. Accession
numbers for genes identified in the Salmonella genomes
are presented in Additional file 1: Table S4 along with their
observed frequency including full matches, partial, frag-
mented and interrupted assemblies.
Genotype-phenotype comparisons
Broth microdilution MICs interpreted with ECOFFs are
classified as wild-type (susceptible) or non-wild-type
(resistant), whereas phenotypic tests interpreted using
clinical breakpoints are classified as resistant or sensi-
tive. ASTs with ‘intermediate’ interpretation results are
classified as sensitive in this study. Resistant or non-
wild-type WGS genotypes are defined by the presence of
one or more resistance determinants for a tested anti-
microbial. Identified genes were matched to their corre-
sponding phenotypes using the schema presented in
Additional file 1: Table S4. Very Major Error (VME) and
Major Error (ME) classifications were assigned to geno-
typic and phenotypic test results based on concordance
with the broth microdilution reference. A VME is
defined by a sensitive or wild-type AST prediction
coupled with a resistant or non-wild-type reference
phenotype. Similarly, MEs are defined by a resistant or
non-wild-type AST prediction with a sensitive or wild-
type reference phenotype. Error rates are presented as
the percentage of VMEs or MEs over the total number
of isolates with the corresponding reference phenotype.
Sensitivity, specificity, positive predictive values, negative
predictive values and 95% confidence intervals (CI) were
calculated using the R bdpv package [27]. Analysis
scripts are available online at: https://github.com/
NMNS93/Mensah_SalmonellaWGS.
Results
Genotype-phenotype comparison: epidemiological cut-off
criteria
Genotyping was concordant with 1007/1122 (89.8%)
broth microdilution AST results interpreted with
ECOFFs (Table 1). One hundred and fifteen discrepan-
cies were observed, resulting in a 4.5% ME rate (n = 28)
and a 17% VME rate (n = 87). Fifty-one (59%) VMEs
were the result of discordant sulfisoxazole and sulfa-
methoxazole predictions. Similarly, genotyping produced
VMEs for all eight gentamicin non-wild-type isolates.
WGS AMR predictions granted 0.83 sensitivity and 0.96
specificity (95%CI 0.94–0.97) overall (Table 2). Excluding
the results for sulfamethoxazole and sulfisoxazole ASTs,
which presented consistently high VMEs, genotyping
was concordant with 857 (93.4%) ASTs. For this subset
excluding sulfamethoxazole and sulfisoxazole, genotyp-
ing presented 0.89 sensitivity and 0.96 specificity.
Genotype-phenotype comparison: clinical breakpoint
criteria
In total, 714 broth microdilution AST results were inter-
preted with clinical breakpoints, representing ASTs for
seven antimicrobials. Genotyping was concordant with
618 (86.6%) broth microdilution reference ASTs, which
was fewer than the 661 (92.6%) agar dilution and 665
(93.1%) disk diffusion results concordant with the refer-
ence (Table 1). Agar dilution produced the highest VME
rate of 17% (n = 45) followed by 16% for genotyping
(n = 43) and 6.93% for disk diffusion (n = 17) (Table 3).
The agar dilution VMEs were split between chloram-
phenicol (n = 14) and streptomycin (n = 16). The major-
ity of genotyping VMEs resulted from sulfamethoxazole
resistance predictions (n = 23), as found using the
ECOFFs. ME rates were highest for genotyping at 12%
(n = 53), followed by 7.14% disk diffusion (n = 32) and
1.79% for agar dilution (n = 8). Streptomycin resistance
predictions were responsible for 43/53 genotyping MEs
and 31/32 disk diffusion MEs. WGS genotyping sensitiv-
ity was 0.84 (95%CI 0.79–0.88); this was lower than disk
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diffusion (0.94 sensitivity, 95%CI 0.90–0.96) yet higher
than agar dilution (0.83 sensitivity, 95%CI 0.78–0.87). In
contrast, agar dilution demonstrated the highest specifi-
city of 0.98 (95%CI 0.97–0.99) followed by disk diffusion
(0.93, 95%CI 0.90–0.95) and genotyping (0.88, 95%CI
0.85–0.91) (Table 3). Excluding ASTs with high error rates
(streptomycin and sulfamethoxazole) resulted in improved
genotyping results of 0.89 sensitivity (95%CI 0.83–0.94),
0.97 specificity (95%CI 0.95–0.99) and 94.7% concordance
(483/510) for the remaining five antimicrobials.
Aminoglycoside resistance
Streptomycin resistance determinants, aadA (n = 60) or
strAB (n = 29), were identified in 67 (65.6%) isolates
(Fig. 1 and Additional file 1: Table S4) resulting in 89%
genotyping concordance with ECOFF interpretations.
Resistance determinants were detected in 6/16
streptomycin wild-type isolates, resulting in MEs (MICs
16 μg/ml; S02606–01, S00795–02, S03632–02, L00777–
11, S02636–11, S02347–12). Genotyping was 55.8% con-
cordant with streptomycin clinical breakpoints as 43/76
streptomycin sensitive isolates (MIC ≤64 μg/ml) con-
tained complete resistance gene hits. AMR determinants
were not found for resistant isolates S02185–06 and
L02428–05, although aadA1 (X68227) was partially as-
sembled in the latter.
Gentamicin resistance determinants were not identi-
fied in the S. Typhimurium genomes. However, seven
isolates with non-wild-type and clinical gentamicin
resistance (S10543–93, S01710–04, S04488–04, L00746–
Table 1 Comparison of WGS-based genotyping and phenotypic ASTs against the broth microdilution reference. Frequency of
isolates assigned to classification groups after phenotypic testing (broth microdilution) and application of interpretive criteria
(epidemiological cut-off and clinical breakpoint). Genotype concordance with classification groups is provided for each interpretive
criterion. Antimicrobials with ‘-‘values were not assessed due to the absence of established breakpoints or susceptibility test data
Antimicrobial Epidemiological cut-off Clinical breakpoint
Non-Wild Type Wild Type Genotype concordance (%) Resistant Sensitive Genotype Concordance (%)
Ampicillin 57 45 95.10 57 45 95.10
Chloramphenicol 49 53 94.12 49 53 94.12
Ciprofloxacin 27 75 96.08 - - -
Gentamicin 8 94 92.16 7 95 93.14
Nalidixic Acid 28 74 95.10 28 74 95.10
Sulfamethoxazole 69 33 76.47 69 33 76.47
Streptomycin 66 36 89.22 26 76 55.88
Sulfisoxazole 73 29 70.59 - - -
Trimethoprim-Sulfamethoxazole (1:19) 33 69 93.14 30 72 96.08
Tetracycline 57 45 89.22 - - -
Trimethoprim 32 70 96.08 - - -
Overall 499 623 89.75 266 448 86.55
Table 2 Sensitivity and specificity of WGS-based antimicrobial resistance predictions against the broth microdilution reference AST.
Epidemiological cut-offs are applied as interpretive criteria for the reference AST
Antimicrobial Genotyping sensitivity (95% CI) Genotyping specificity (95% CI)
Ampicillin 0.96 (0.88–1) 0.93 (0.82–0.99)
Chloramphenicol 0.94 (0.83–0.99) 0.94 (0.84–0.99)
Ciprofloxacin 0.85 (0.66–0.96) 1 (0.95–1)
Gentamicin 0 (0–0.37) 1 (0.96–1)
Nalidixic Acid 0.82 (0.63–0.94) 1 (0.95–1)
Sulfamethoxazole 0.67 (0.54–0.78) 0.97 (0.84–1)
Streptomycin 0.92 (0.83–0.97) 0.83 (0.67–0.94)
Sulfisoxazole 0.62 (0.5–0.73) 0.93 (0.77–0.99)
Trimethoprim-Sulfamethoxazole 0.88 (0.72–0.97) 0.96 (0.88–0.99)
Tetracycline 0.95 (0.85–0.99) 0.82 (0.68–0.92)
Trimethoprim 0.94 (0.79–0.99) 0.97 (0.9–1)
Overall 0.83 (0.79–0.86) 0.96 (0.94–0.97)
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11, S03924–11, S06636–12 and S00478–13) had a par-
tially assembled aac3-IVa gene (X01385). An additional
NWT strain (L02428–05) contained this partial assembly
and presented a lower MIC at one doubling dilution
above the 2 μg/ml gentamicin ECOFF.
Beta-lactam resistance
Fifty-eight isolates (56.8%) contained either blaTEM
(n = 26) or blaCARB (n = 32) (Fig. 1 and Additional file
1: Table S4) conferring ampicillin resistance. Concord-
ance using both ECOFFs and clinical breakpoints was
Table 3 Sensitivity and specificity of phenotypic ASTs and genotypic AMR predictions against the broth microdilution reference AST.
Clinical breakpoints are applied as interpretive criteria for all ASTs
Antimicrobial Sensitivity (95% CI) Specificity (95% CI)
Disk diffusion Agar dilution Genotyping Disk diffusion Agar dilution Genotyping
Ampicillin 0.95 (0.85–0.99) 0.95 (0.85–0.99) 0.96 (0.88–1) 1 (0.92–1) 1 (0.92–1) 0.93 (0.82–0.99)
Chloramphenicol 0.92 (0.8–0.98) 0.71 (0.57–0.83) 0.94 (0.83–0.99) 0.98 (0.9–1) 0.98 (0.9–1) 0.94 (0.84–0.99)
Gentamicin 0.71 (0.29–0.96) 0.86 (0.42–1) 0 (0–0.41) 1 (0.96–1) 1 (0.96–1) 1 (0.96–1)
Nalidixic Acid 0.82 (0.63–0.94) 0.75 (0.55–0.89) 0.82 (0.63–0.94) 1 (0.95–1) 0.96 (0.89–0.99) 1 (0.95–1)
Sulfamethoxazole 0.97 (0.9–1) 0.97 (0.9–1) 0.67 (0.54–0.78) 1 (0.89–1) 0.94 (0.8–0.99) 0.97 (0.84–1)
Streptomycin 0.96 (0.8–1) 0.38 (0.2–0.59) 0.92 (0.75–0.99) 0.59 (0.47–0.7) 1 (0.95–1) 0.43 (0.32–0.55)
Trimethoprim-Sulfamethoxazole 1 (0.88–1) 0.93 (0.78–0.99) 0.97 (0.83–1) 1 (0.95–1) 0.97 (0.9–1) 0.96 (0.88–0.99)
Overall 0.94 (0.9–0.96) 0.83 (0.78–0.87) 0.84 (0.79–0.88) 0.93 (0.9–0.95) 0.98 (0.97–0.99) 0.88 (0.85–0.91)
Fig. 1 Frequency of Salmonella enterica serovar Typhimurium isolates identified with each reference sequence. Listed reference sequences are
putative resistance genes fully assembled from isolate genomes by ARIBA
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95%, with two VMEs (S04635–04, S04655–09; MIC >
64 μg/ml) and only three MEs (S02606–01, L00777–
11, L01210–11; MIC ≤2 μg/ml). MEs were due to
genotype hits for blaCARB-2 (M690858), blaTEM-1B
(JF910132) and blaTEM-206 (KC783461) respectively.
Phenicol resistance
Phenicol resistance determinants floR (n = 31), cmlA1
(n = 16) and catA1 (n = 2) were present in 46 isolates
(45%) (Fig. 1 and Additional file 1: Table S4). All chlor-
amphenicol non-wild-type isolates were also classified as
resistant using clinical breakpoints. Genotyping identi-
fied chloramphenicol AMR genes in 46/49 R/NWT
isolates, and 3/53 S/WT isolates, resulting in 94% AMR
prediction concordance for this antimicrobial using both
interpretive criteria. Three isolates with MEs (S10423–
92, catA1 (V00622); S02606–01, floR (AF118107);
L00777–11, cmlA (M64556)) had MICs at the 8 μg/ml
clinical breakpoint, one doubling dilution from the
16 μg/ml ECOFF. Of three isolates with VMEs (S06618–
99, S01117–00, S04635–04), a partial floR gene was
assembled from one genome (S04635–04).
Quinolone resistance
Twenty-two isolates harboured point mutations in the
quinolone resistance determining region of gyrA: Ser83-
Phe (n = 10), Ser83-Tyr (n = 1), Asp87-Asn (n = 9) and
Asp87-Try (n = 2) (Fig. 1 and Additional file 1: Table S4)
. No other known S. Typhimurium quinolone resistance
mutations were detected. Additionally, isolate S06001–
08 contained the plasmid-mediated quinolone resistance
gene qnrB19 (HM146784). Isolates classified as nalidixic
acid resistant using clinical breakpoints were also
classified as non-wild-type using ECOFFs, therefore
genotypic resistance determinants showed 95% concord-
ance for both interpretive criteria. These discrepancies
resulted from a lack of nalidixic acid resistance determi-
nants in five isolates with MICs > 128 μg/ml (S01117–
00, S02606–01, S04635–04, S04655–09, S06636–12).
Genotype-phenotype correlations for ciprofloxacin mir-
rored nalidixic acid results using ECOFFs except in the
case of S6636–12, which granted one fewer VME due to
a 0.03 μg/ml WT ciprofloxacin MIC.
Sulfonamide and trimethoprim resistance
Sulfonamide resistance determinants sul1 (n = 15), sul2
(n = 29) and sul3 (n = 16) were present in 47 isolates
(46.1%) (Fig. 1 and Additional file 1: Table S4). For
sulfamethoxazole reference ASTs, all isolates classified
as resistant using clinical breakpoints were also classified
as non-wild-type using ECOFFs. Sulfamethoxazole AMR
gene presence resulted in 76% concordance for both
interpretive criteria, resulting from 23 VMEs and 1 ME
(L00777–11; MIC 64 μg/ml; sul2 (GQ421466), sul3
(AJ459418)). For sulfisoxazole reference ASTs inter-
preted with ECOFFs, sul genes presence produced 71%
genotyping concordance. Twenty-eight isolates had
genotyping VMEs. Two sul wild-type isolates had MEs:
L00777–11 with sul2 and sul3 and S02347–12 with sul2.
Resistance to folate synthesis inhibitors containing
trimethoprim was predicted by the presence of dfrA
gene variants, which were identified in 32 isolates (dfrA1
(n = 4), dfrA12 (n = 17) and dfrA14 (n = 11)). Trimetho-
prim AST results were classified using the > 2 μg/ml
ECOFF and the resulting genotype concordance was
96% for WT and NWT ASTs. Two MEs were detected
in isolates with 0.25 μg/ml trimethoprim MICs: S00285–
01 with dfrA14 (DQ388123) and L00777–11 with dfrA12
(AB571791). Classifications for the sulfamethoxazole-
trimethoprim compound (SXT) differed between inter-
pretive criteria, producing different genotyping correla-
tions. Genotyping concordance was 93% for SXT
interpreted with the 1 μg/ml ECOFF and 96% for SXT
interpreted with the 4 μg/ml clinical breakpoint. MEs for
both interpretive criteria were the result of genotype pre-
dictions for the same three isolates (dfrA14 (DQ388123)
in S00285–01; dfrA12 (AB571791) in S01710–04 and
L00777–11). Whereas genotyping predictions compared
with SXT clinical breakpoint interpretations produced
only one VME (S02202–01), predictions compared with
SXT ECOFF interpretations produced four (S02202–01,
S07053–03, S04635–04, S04055–07).
Tetracycline resistance
Sixty-two isolates harboured tetracycline resistance de-
terminants tetA (n = 15), tetB (n = 14), tetC (n = 4) and
tetG (n = 31) (Fig. 1 and Additional file 1: Table S4).
Genotyping concordance was 89% using the tetracycline
> 8 μg/ml ECOFF for interpretation. MEs were found in
eight isolates with tetracycline MICs ≤4 μg/ml (S10423–
92, S02202–01, S02606–01, S03249–01, S00795–02,
S06216–03, L00777–11 and S02347–12). Discrepancies
resulted from hits against tetA (AJ517790; n = 4), tetG
(AF071555; n = 3) and tetB (AF326777; n = 1). Three
isolates with VMEs had tetracycline MICs ≥32 μg/ml
(S01117–00, S02357–04 and S04635–04).
Discussion
Comparisons of AMR genotyping methods to pheno-
typic ASTs are essential to determine the true utility of
WGS for AMR surveillance. This study contributes to
the growing body of evidence by providing genotype-
phenotype comparisons for both epidemiological and
clinical contexts, and in comparing multiple phenotypic
ASTs. S. Typhimurium AMR genotypes were 89.8%
concordant for ASTs interpreted with ECOFFs across 11
antimicrobials. Clinical breakpoints were available for
seven of these antimicrobials and after applying these
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criteria to the same broth microdilution dataset, WGS
concordance was 86.6%. A further comparison demon-
strated that agar dilution and disk diffusion presented
more favourable results than genotyping with 92.6 and
93.1% concordance respectively (Table 3). Genotyping
predictive errors were more common for specific antimi-
crobials. For example, excluding sulfonamides in ECOFF
interpretations raised concordance to 93.4%. Genotyping
concordance was noticeably lower for sulfamethoxazole
ASTs (76%) than the trimethoprim-sulfamethoxazole
compound (93%) ASTs. However, this only reflects the
predictive accuracy of different AMR genes identified as
sulfonamides and trimethoprim inhibit enzymes at dis-
parate stages of the folate synthesis pathway, through
different molecular mechanisms [28]. Similarly for clin-
ical breakpoint interpretations, excluding sulfamethoxa-
zole and streptomycin phenotypes raised concordance to
94.7%. This demonstrates that genotyping predictions
may be more accurate than agar dilution and disk diffu-
sion ASTs for specific antimicrobial classes.
Interestingly, 44/96 clinical breakpoint errors and 53/
115 ECOFF errors occurred where isolate MICs were
within 1 doubling dilution of the classification
breakpoint. Interpretive criteria for clinical breakpoints
typically include ‘intermediate’ classification ranges that
reflect the concentration range for which isolates con-
tain resistance determinants but do not present MICs
past the resistance threshold. In this analysis, intermedi-
ates were classed as susceptible, therefore isolates in this
range may contribute to these errors despite otherwise
accurate genotyping calls. Such increases in error
frequency near MIC breakpoints were especially true for
streptomycin comparisons, where 39/45 mismatches
were within 1 dilution of the clinical breakpoint.
Misclassification of streptomycin resistance by WGS
genotyping has been well documented in enterobacteria,
including Salmonella and E. coli spp. [6–8, 29–31].
These mismatches have been attributed to insufficient
breakpoints and gene inactivation mechanisms. For
example, environmental and mutational activation of the
cryptic aadA gene can increase expression of strepto-
mycin resistance in Salmonella enterica [32]. We applied
the ≥64μg/ml breakpoint used by McDermott et al.
(2016) [6] to identify highly-resistant isolates. Both CLSI
and EUCAST interpretation tables note that for Salmon-
ella spp., aminoglycosides may appear active in vitro but
are not effective clinically and should not be reported as
susceptible. Therefore, a lack of clinical use and
difficulty in classification contributes to the absence of
clinical breakpoints for streptomycin. Tyson et al. (2016,
[33]) suggest incorporating genotypic resistance determi-
nants into predictions of streptomycin breakpoints and
such refinements to interpretive criteria may improve
genotyping prediction accuracy against.
A number of genotyping predictive errors were accom-
panied by interrupted, fragmented or partial assemblies
of genes identified using ARIBA. As these do not consti-
tute complete genes, they were not reported for these
isolates. All gentamicin non-wild-type (n = 8) isolates
were inaccurately classified, however an interrupted
aac3-IVa gene (X01385) was identified by ARIBA in 7/8
non-wild-type isolates, which were also resistant above
the gentamicin clinical breakpoint. In addition, we ac-
knowledge that the low gentamicin resistance prevalence
affects the reliability of genotyping specificity estimates.
In 22 isolates with sulfonamide VME mismatches,
fragmented sul1 genes (CP002151 or EU855787) were
identified by ARIBA. Resistance mechanisms may there-
fore have variable detection rates dependent on factors
such as sequencing quality and genomic arrangement.
Multiple studies have reported that resistomes deter-
mined by WGS show a high correlation with clinical re-
sistance by broth microdilution ASTs in Gram-negative
bacteria. McDermott et al. (2016) observed a genotype-
phenotype correlation of 99% in 640 Salmonella [6] and
more recently, Neuert et al. identified genotyping
discrepancies in only 0.17% of isolate-antimicrobial com-
binations [14]. Similarly, Tyson et al. report a 98.5%
overall correlation in 76 E. coli [8] and Zhao et al. found
a 99.2% correlation in 114 Campylobacter isolates [34].
Including these studies, sensitivity and specificity of
WGS-based AMR predictions against ASTs in a range of
bacterial species has been reported at ≥96%. [9, 35, 36].
Previous studies also quote low WGS susceptibility testing
error rates [35, 37] within the bounds of those deemed tol-
erable by the US FDA susceptibility testing devices (< 1.5
confidence range limit for VMEs and < 3.0% for MEs, with
a minimum category agreement of > 89.9%)[38]. We
observed lower levels of category agreement and higher
error rates between WGS genotypes and S. Typhimurium
phenotypes than previously reported. However, this study
identifies a new lower-bound genotyping accuracy range
for specific antimicrobials and provides a comparison with
alternative phenotypic methods. Additionally, several stud-
ies present genotype-phenotype comparisons using in-
house scripts and unpublished AMR gene databases from
which results cannot be reproduced. Here, we leverage the
open-source bioinformatics algorithm ARIBA along with
the Resfinder and Pointfinder databases. ARIBA has the
advantage of a local assembly method that accurately
determines interrupted or partially present genes from
sequence data. Data pre-processing and analysis proce-
dures are provided as R scripts.
The observed misclassifications point to the current
limits of WGS-based genotyping. Genotyping approaches
require AMR sequence databases containing known re-
sistance genes. Although WGS may accurately sequence
novel genetic mechanisms, clinically resistant isolates may
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be falsely labelled as sensitive if these mechanisms are not
represented in AMR databases. Additionally, WGS-based
genotyping methods used in this study are unable to
account for mechanisms that attenuate or inhibit gene ex-
pression. At the molecular level this includes factors such
as the proximity of class 1 integron promoter regions, the
copy number of gene cassettes and the potency of primary
and secondary promoters [30, 39, 40]. The limitations
described are inherent to the challenge of predicting AMR
from the presence of known resistance genes alone.
The current evidence base for using WGS to infer
antimicrobial susceptibility requires significant expan-
sion [15]. Alternatives to the reference broth microdilu-
tion AST remain relevant to diagnostic and surveillance
laboratories worldwide, therefore the inclusion of agar
dilution and disk diffusion methods in this study pro-
vides context for these institutions to evaluate the use of
WGS to predict S. Typhimurium AMR susceptibility.
Over time the increasing predictive power of computa-
tional analysis, coupled with decreasing sequencing
costs, will make WGS a more viable AMR screening tool
for laboratories worldwide. Cost-benefit assessments
should factor in the extended utility of WGS beyond
AMR screening. WGS presents a powerful assay for a
genotype-driven approach to epidemiology, capable of
detecting AMR genes, clonal and plasmid typing, detect-
ing mechanisms for gene transfer and virulence, and the
source attribution of novel isolates. Future work should
identify the role of downstream events that reduce sus-
ceptibility in discordant predictions where gene presence
does not account for observed phenotypes. As further
replicative and investigative studies identify new resist-
ance mechanisms and improve the reliability of AMR
sequence databases, a decrease in error rates may see
this technical method supplement, and potentially super-
sede, established assays.
Conclusion
We compared WGS for AMR prediction against 3
phenotypic tests including disk diffusion, agar dilution
and the gold standard broth microdilution representing
clinical and veterinary screening environments. The
European Committee on Antimicrobial Susceptibility
testing (EUCAST) subcommittee recommends ECOFFs
as the primary interpretive criteria for WGS compari-
sons against phenotypic ASTs, along with secondary
analyses using clinical breakpoints. Genotypic predic-
tions correctly characterised isolates as wild-type or
non-wild-type for 89.8% (1007/1122) of phenotypic
assays with 0.83 sensitivity and 0.96 specificity using
broth microdilution as the reference susceptibility test
method. Genotyping was comparable with disk diffusion
(sensitivity 0.94, specificity 0.93) and agar dilution (sensi-
tivity 0.83, specificity 0.98) resistance phenotypes where
antimicrobials with high very major error rates were ex-
cluded, producing 0.89 sensitivity and 0.97 specificity.
Results from this study indicate that with further work
to reduce the error rates for specific antimicrobials,
WGS would serve as an effective screening tool for the
tracking of AMR mechanisms in S. Typhimurium.
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